<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590638</url>
  </required_header>
  <id_info>
    <org_study_id>Mmehak</org_study_id>
    <nct_id>NCT04590638</nct_id>
  </id_info>
  <brief_title>Comparison Between Effect of Adrenaline and Without Adrenaline in Tumescent Solutions on Bleeding Control of Skin Graft Donor Site.</brief_title>
  <official_title>Comparison Between Effect of Adrenaline and Without Adrenaline in Tumescent Solutions on Bleeding Control of Skin Graft Donor Site.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dow University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to appraise if various concentration of adrenaline containing&#xD;
      tumescent has any significant role in bleeding at skin graft donor site bleeding through&#xD;
      photographic assessment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumescent solutions will be prepared by adding 30cc of Ringer's lactate and 10cc of&#xD;
      lignocaine 2%, with 1cc of adrenaline of 1:200,000 (which will be prepared by adding 1cc of&#xD;
      adrenaline of 1:1000 conc. with 200ml of normal saline marked as solution &quot;A&quot; and without&#xD;
      adrenaline marked as solution &quot;B&quot; to form the two different tumescent solutions. Both&#xD;
      solutions with be topically applied in soaked gauzes for around 10 minutes. Solution A will&#xD;
      be applied over the anterior side of thigh while solution B will be applied over lateral side&#xD;
      of thigh.&#xD;
&#xD;
      Tumescent solutions will be prepared around 10 minutes before applying. After 10 min&#xD;
      Split-thickness skin graft donor sites will be harvested with a Dermatome adjusted on with a&#xD;
      randomized setting to harvest a fixed depth of wound depth. After harvesting skin graft the&#xD;
      donor site wound will be photographed.&#xD;
&#xD;
      The apparent severity of bleeding will be scored on an ordinal scale from 0 to 5 (0=no&#xD;
      bleeding/staining, 1=minimal bleeding/staining, 2=mild bleeding/staining, 3=moderate&#xD;
      bleeding/staining, 4=moderately severe bleeding/staining, 5=severe bleeding/staining by two&#xD;
      independent surgeons. At last photographs will be compared with pre-infiltration records in&#xD;
      each side. Skin graft donor and recipient site will be inspected on the 5th post-operative&#xD;
      day&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2020</start_date>
  <completion_date type="Actual">March 17, 2021</completion_date>
  <primary_completion_date type="Actual">March 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ordinal scale</measure>
    <time_frame>30minutes</time_frame>
    <description>The apparent severity of bleeding will be scored on an ordinal scale from 0 to 5 (0=no bleeding/staining, 1=minimal bleeding/staining, 2=mild bleeding/staining, 3=moderate bleeding/staining, 4=moderately severe bleeding/staining, 5=severe bleeding/staining by two independent surgeons.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Bleeding Time</condition>
  <arm_group>
    <arm_group_label>Tumescent with adrenaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution containing adrenaline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumescent without adrenaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution not containing adrenaline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tumescent with adrenaline</intervention_name>
    <description>skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.</description>
    <arm_group_label>Tumescent with adrenaline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tumescent without adrenaline</intervention_name>
    <description>skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.</description>
    <arm_group_label>Tumescent without adrenaline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age above 18 years&#xD;
&#xD;
               -  both genders&#xD;
&#xD;
               -  non hypertensive patients&#xD;
&#xD;
               -  Hemoglobin levels more than 10 g/dl&#xD;
&#xD;
               -  Platelet count above 150 x 10E9/L&#xD;
&#xD;
               -  Wounds for more than 6 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Hypertensive patients,&#xD;
&#xD;
               -  Bleeding tendencies (Disorder),&#xD;
&#xD;
               -  Immune-compromised,&#xD;
&#xD;
               -  Familial history of bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mahak</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>1234</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 11, 2020</study_first_submitted>
  <study_first_submitted_qc>October 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>August 21, 2021</last_update_submitted>
  <last_update_submitted_qc>August 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dow University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Mahak Ali</investigator_full_name>
    <investigator_title>MahakA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

